The North America Urinalysis Market is experiencing robust growth due to rising prevalence of urinary tract infections, increasing geriatric population, and advancements in automated urinalysis systems. The market size was valued at USD 1,050 Million in 2025 and is projected to reach USD 2,420 Million by 2035, expanding at a CAGR of 7.8% from 2024 to 2035.
The economic impact of tariffs on "North America Urinalysis Market".
Market Growth Drivers
Increasing Prevalence of Chronic Diseases: The surge in diabetes, kidney disorders, and hypertension has significantly driven the demand for urinalysis tests in North America. According to Siemens Healthineers, chronic kidney disease affects 1 in 7 adults, resulting in increased diagnostic needs. As chronic ailments continue to put a strain on healthcare systems, the urgent need for early and accurate diagnosis using automated urinalysis analyzers further catalyzes market expansion.
Technological Advancements in Urinalysis: Innovation in urinalysis devices, including the integration of artificial intelligence and automation, is enhancing test accuracy and throughput. Companies such as Beckman Coulter have introduced fully-automated urinalysis solutions that reduce human error and speed up diagnosis, supporting healthcare providers in the effective identification of patient health conditions and enabling faster clinical decisions.
Market Trends
Adoption of Home-based and Point-of-Care Testing: The growing emphasis on decentralizing diagnostic testing has led to higher adoption rates of home-based urinalysis solutions and point-of-care analyzers. Abbott Laboratories, for instance, has introduced portable devices enabling remote monitoring of patients with chronic illnesses, notably improving patient compliance and reducing the burden on hospital laboratories.
Integration of Digital Health Records: Urinalysis equipment is increasingly designed to be compatible with electronic health records (EHR) systems, streamlining data handling and analysis. Becton, Dickinson and Company (BD) has focused on interoperability and connectivity in their latest urinalysis analyzers, allowing healthcare providers to seamlessly integrate diagnostic results into patient management platforms.
Market Opportunities
Expansion of Telehealth Services: The post-pandemic surge in telemedicine is creating new opportunities for urinalysis market players. Companies like QuidelOrtho are exploring ways to link urinalysis results with telehealth platforms, enabling real-time consultations and timely interventions.
Rising Investments in Personalized Medicine: North America is witnessing increased investments in precision and personalized medicine, opening doors for advanced urinalysis solutions tailored for patient-specific diagnostics and monitoring. This trend offers companies avenues for developing innovative solutions targeting niche patient subgroups.
North America Urinalysis Market Revenue (USD Million), 2020-2035
The chart below illustrates the steady and robust growth of the North America Urinalysis Market from 2020 to 2035. Beginning at USD 683 Million in 2020, the market has shown a consistent upward trajectory, owing to increased adoption of technologically advanced diagnostic tools and rising incidences of diseases requiring urinalysis. By 2025, the market is expected to cross USD 1,050 Million, and projections suggest it will more than double by 2035, reaching USD 2,420 Million. This sustained growth is reflective of both expanding demand in clinical settings and advancements in home-based diagnostic applications across the region.
North America Urinalysis Market Share by Region, 2025
As depicted, the United States dominates the North America Urinalysis Market in 2025, accounting for 78% of the market share, attributed to its advanced healthcare infrastructure and high adoption rates of automated diagnostic technologies. Canada follows with 15%, leveraging growing investments in public healthcare and increased screening initiatives. Mexico holds 5% of the market, primarily driven by expanding diagnostic capabilities in urban centers. Other regions, including Caribbean nations, share the remaining 2%. This regional analysis underscores the significant impact of healthcare investments and technological adoption rates within the various geographic segments of North America.
Recent Developments in the North America Urinalysis Market
In March 2024, Beckman Coulter announced the launch of their next-generation fully-automated urinalysis analyzer, 'DxU Iris,' in North America, allowing laboratories to process higher sample volumes with greater accuracy and minimal manual intervention. This development enhances workflow efficiency and supports faster patient diagnosis, especially in high-throughput settings.
In April 2024, Siemens Healthineers and Epic Systems unveiled a breakthrough strategic partnership to jointly develop integrated digital urinalysis solutions. This collaboration aims to enhance data transfer between urinalysis devices and electronic health records, providing seamless clinical decision support and improving patient outcomes across a range of healthcare facilities in the region.
In May 2024, Abbott Laboratories received FDA clearance for their new home-based urinalysis test kit, 'UroCheck,' which enables patients to self-administer tests and upload results directly to healthcare providers via a secured mobile app. This advancement supports the growing trend towards remote patient monitoring and helps address the diagnostic needs of individuals with mobility or access challenges.
Press Releases